Last reviewed · How we verify

Palcebo; Carboplatin; Etoposide；Radiotherapy

Jiangsu HengRui Medicine Co., Ltd. · Phase 3 active Small molecule

Palcebo; Carboplatin; Etoposide；Radiotherapy is a Chemotherapy combination + radiotherapy Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Likely small cell lung cancer or other solid tumors (specific indication not provided).

This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.

This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm. Used for Likely small cell lung cancer or other solid tumors (specific indication not provided).

At a glance

Generic namePalcebo; Carboplatin; Etoposide；Radiotherapy
SponsorJiangsu HengRui Medicine Co., Ltd.
Drug classChemotherapy combination + radiotherapy
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Carboplatin is a platinum-based alkylating agent that cross-links DNA and prevents replication. Etoposide is a topoisomerase II inhibitor that causes DNA breaks during cell division. Radiotherapy delivers ionizing radiation to directly damage tumor DNA. Together, these modalities create multiple mechanisms of cancer cell death in a phase 3 trial context.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Palcebo; Carboplatin; Etoposide；Radiotherapy

What is Palcebo; Carboplatin; Etoposide；Radiotherapy?

Palcebo; Carboplatin; Etoposide；Radiotherapy is a Chemotherapy combination + radiotherapy drug developed by Jiangsu HengRui Medicine Co., Ltd., indicated for Likely small cell lung cancer or other solid tumors (specific indication not provided).

How does Palcebo; Carboplatin; Etoposide；Radiotherapy work?

This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.

What is Palcebo; Carboplatin; Etoposide；Radiotherapy used for?

Palcebo; Carboplatin; Etoposide；Radiotherapy is indicated for Likely small cell lung cancer or other solid tumors (specific indication not provided).

Who makes Palcebo; Carboplatin; Etoposide；Radiotherapy?

Palcebo; Carboplatin; Etoposide；Radiotherapy is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What drug class is Palcebo; Carboplatin; Etoposide；Radiotherapy in?

Palcebo; Carboplatin; Etoposide；Radiotherapy belongs to the Chemotherapy combination + radiotherapy class. See all Chemotherapy combination + radiotherapy drugs at /class/chemotherapy-combination-radiotherapy.

What development phase is Palcebo; Carboplatin; Etoposide；Radiotherapy in?

Palcebo; Carboplatin; Etoposide；Radiotherapy is in Phase 3.

What are the side effects of Palcebo; Carboplatin; Etoposide；Radiotherapy?

Common side effects of Palcebo; Carboplatin; Etoposide；Radiotherapy include Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Alopecia, Peripheral neuropathy, Radiation dermatitis, Fatigue.

Related